Stay updated with breaking news from Fuchs Focus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial ResultsAdditional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022Phase 2/3 Sirius and Celeste clinical trials of ult...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. ProQR Announces First Quarter 2021 Operating and Financial Results ProQR Therapeutics N.V.May 6, 2021 GMT Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022 Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retinitis pigmentosa, with plans to advance the program into two pivotal Phase 2/3 trials before year end Exclusive worldwide license and discovery c...